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Abstract
Background: In addition to regulating platelet function, the G protein-coupled sub-family member Proteinase-
activated receptor-1 (PAR1) has a proposed role in the development of various cancers, but its exact role and
mechanism of action in the invasion, metastasis, and proliferation process in gastric cancer have yet to be
completely elucidated. Here, we analyzed the relationship between PAR1 activation, proliferation, invasion, and the
signaling pathways downstream of PAR1 activation in gastric cancer.
Methods: We established a PAR1 stably transfected MKN45 human gastric cancer cell line (MKN45/PAR1) and
performed cell proliferation and invasion assays employing this cell line and MKN28 cell line exposed to PAR1
agonists (a-thrombin and TFLLR-NH2). We also quantified NF-B activation by electrophoretic mobility shift assay
(EMSA) and the level of Tenascin-C (TN-C) expression in conditioned medium by ELISA of MKN45/PAR1 following
administration of a-thrombin. A high molecular weight concentrate was derived from the resultant conditioned
medium and subsequent cultures of MKN45/PAR1 and MKN28 were exposed to the resultant concentrate either in
the presence or absence of TN-C-neutralizing antibody. Lysates of these subsequent cells were probed to quantify
levels of phospholyrated Epidermal Growth Factor Receptor (EGFR).
Result: PAR1 in both PAR1/MKN45 and MKN28 was activated by PAR1 agonists, resulting in cell proliferation and
matrigel invasion. We have shown that activation of NF-B and EGFR phosphorylation initially were triggered by
the activation of PAR1 with a-thrombin. Quantitative PCR and Western blot assay revealed up-regulation of mRNA
and protein expression of NF-B target genes, especially TN-C, a potential EGFR activator. The suppressed level of
phosphorylated EGFR, observed in cells exposed to concentrate of conditioned medium in the presence of TN-C-
neutralizing antibody, identifies TN-C as a putative autocrine stimulatory factor of EGFR possibly involved in the
sustained PAR1 activation responses observed.
Conclusion: Our data indicate that in gastric carcinoma cells, PAR1 activation can trigger an array of responses
that would promote tumor cell growth and invasion. Over expression of NF-B, EGFR, and TN-C, are among the
effects of PAR1 activation and TN-C induces EGFR activation in an autocrine manner. Thus, PAR1 is a potentially
important therapeutic target for the treatment of gastric cancer.
Background
A dysregulation of the coagulation cascade in the setting
of human tumors has been recognized for over a cen-
tury [1]. In particular, active thrombin has been found
to play an important role in terms of tumor behavior,
affecting a variety of cancer-related processes including
invasion, metastasis and tumor cell growth [2,3]. In
large part, thrombin initiates cellular effects by cleaving
and thus activating a novel set of Proteinase-activated
receptors (PARs 1 and 4; but not PAR2), that are mem-
bers of the G-protein-coupled receptor (GPCR) super-
family [4-8]. Although able to activate PARs 1 and 4,
thrombin is not able to activate PAR2, which is a target
for trypsin [9]. PAR1 has been found to be instrumental
in cell growth and invasion of tumor-derived cells
[10,11]. In addition to regulating cell function by the
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activation of metalloproteinase-2 (MMP2) [12]. Apart
from serine proteinases that can activate PARs to affect
cancer cell behavior, MMPs have for some time been
known to be involved in cancer metastasis and invasion
[13-17]. Surprisingly, MMP1 has been observed, like
thrombin, to regulate invasion and tumorigenesis of
breast cancer-derived cells by a process involving PAR1
[18], providing an important link between tumor gener-
ated metalloproteinases and PAR signaling. Additionally
the existence of cross-talk between GPCR and EGFR
signaling systems has been established in various cancer
cells and has been found to promote cancer cell prolif-
eration and migration through EGFR transactivation in
colon cancer and renal cell carcinoma. MMPs are
required by some GPCRs which suggest a possible role
for MMPs in the PAR1 activation system as PAR1 is a
subfamily of GPCR [19,20]. In prostate cancer-derived
cells, PAR1 over-expression has also been documented
and has been linked to PAR1-stimulated activation of
NF-B, with an increase in NF-B-regulated inflamma-
tory cytokines like IL-6 and IL-8 [21]. The exact role
and mechanism of action of PAR1 in this process
remains unclear.
In our previous work, using an immunohistochemical
approach with gastric carcinoma tissue, we found that
the expression of PAR1, along with a metalloproteinase
known to activate PAR1 (MMP1) was associated with
poorer prognosis, compared with expression-negative
tumors [22]. In this study, we hypothesized that PAR1
would play an important role in gastric carcinoma cells.
To test this hypothesis, wee v a l u a t e dt h ei m p a c to f
PAR1 activation in gastric cancer-derived cells. Our data
show that the signaling pathways stimulated by PAR1 in
the gastric cancer-derived cells mediate proliferation
and invasion, and Tenascin-C (TN-C) might play an
important role in this signaling pathways stimulated by
PAR1.
Methods
Reagents
An antibody against PAR1 (clone WEDE15) was pur-
chased from BECKMAN COULTER (Fullerton, CA,
USA). Anti-TN-C was purchased from IBL (Gunma,
Japan) and TN-C-neutralizing antibody (Clone BC24)
[23] was from Sigma-Aldrich (St. Lois, MO, USA). Anti-
Bcl-2, phospho-specific antibodies against EGFR (clone
20G3) and phosphotyrosyl-1173 EGFR (clone 9H2) were
purchased from Upstate Biotech (Temecula, CA, USA).
Anti-NF-B-p50 and -p52 were from Santa-Cruz Bio-
technology (Santa-Cruz, CA, USA). Anti-cIAP1 was
from R&D systems (Minneapolis, MN, USA). Anti-
GAPDH was from IMGENEX (San Diego, CA, USA).
Human a-thrombin was purchased from Sigma-Aldrich
(catalog #T1063). The selective PAR1 antagonist
SCH79797 (catalog #1592) (IC50 = 70 nM) and PAR1
agonist TFLLR-NH2 (catalog #1464) were purchased
from Tocris Bioscience (Anonmouth, UK) [24]. The
NF-B inhibitor Caffeic acid phenethyl ester (CAPE)
(IC50 = 25 μg) was purchased from Biomol (Plymouth
Meeting, PA, USA) [25].
Cell Culture
The human gastric cancer cell lines, MKN28, MKN45
MKN74, NUGC2, NUGC3, and KATOIII cells were
obtained from the Riken Cell Bank (Tsukuba, Japan).
TMK-1 was a gift from Dr. S Fushida (Kanazawa Uni-
versity, Japan). Cells were cultured at 37°C in 5% CO2 in
RPMI-1640 medium containing 10% fetal bovine serum
(FBS). Cells were propagated by mechanical re-suspen-
sion using a scraper, without the use of trypsin.
Reverse transcription-PCR and quantitative RT-PCR
analysis
Total RNA was extracted from gastric cancer cells with
ISOGEN reagent (NipponGene, Tokyo, Japan). Single-
strand cDNA prepared from 3 μgt o t a lR N Au s i n g
MMLV reverse transcriptase (GIBCO, Calabasas, CA,
USA) with an oligo (dT)14 primer that was used as a tem-
plate for reverse transcription-PCR (RT-PCR) or quanti-
tative-PCR (qPCR). The following primer pairs were
used: GAPDH/5′-GGGAGCCAAAAGGGTCATCATCT-
3′ and 5′-GACGCCTGCTTCACCACCTTCTTG-3′;a n d
PAR1/5′-TGTGAACTGATCATGTTTATG -3′ and 5′-
TTCGTAAGATAAGAGATATGT -3′.
qPCR analysis was also done with a PCR mixture con-
taining each primer and SYBR Green master mix (Qia-
gen, Hilden, Germany). The PCR primer pairs for the
NF-B target genes were custom made (Hokkaido Sys-
tem Science, Hokkaido, Japan). Each sample was exam-
ined in triplicate and the amounts of cDNAs were
normalized with respect to those of a GAPDH internal
control.
Construction of PAR1 expression plasmid
A human PAR1 cDNA sequence was isolated by PCR
from a NUGC3. We amplified the PAR1 cDNA using a
primer set as follows: PAR1-CX for the 5′ primer,
GGGGATCCCGGCAGAGCCCGGGACAATG; and
PAR1-DX for the 3′ primer, GGGAATTCTCCCAG-
CAGTCCCTTTTCC. Both primers incorporated 5′-
BamH1 and 3′-EcoR1 sites, respectively. We amplified
the BamH1 and EcoR1 site-tagged full-length PAR1
f r a g m e n t s ,a n dc l o n e dt h e mi n t oap c D N A 3 . 1( I n v i t r o -
gen, Carlsbad, CA, USA). Positive clones (pcDNA3.1-
PAR1) were isolated and validated by DNA sequencing.
T h es e q u e n c ea g r e e dw i t ht h eG e n e b a n kr e c o r d :
NM001992.
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MKN45 cells were transfected using LipofectAMINE2000
(Invitrogen) and pcDNA3.1-PAR1 (MKN45/PAR1) or
pcDNA3.1-empty-vector alone (for MKN45/mock as the
control). Individual G418 resistant (0.75 mg/ml) clones
were picked and analyzed for PAR1 expression by RT-
PCR and immunoblotting of total cell extract.
Western blot
Total cell protein was extracted using RIPA buffer. Pro-
teins in the lysate were resolved by SDS-PAGE using a
5-20% SuperSep gel (Wako, Osaka, Japan). The resolved
proteins were transferred to nitrocellulose membrane.
Protein bands were incubated with primary antibody
overnight at 4°C. Signals were visualized by enhanced
chemiluminescence according to the manufacturer’s
instructions (GE Healthcare, Buckinghamshire, UK).
Cell growth analysis
To examine the in vitro cell growth rate, MKN45/mock,
MKN45/PAR1 and MKN28 cells were seeded into 24-
well plates at 1.0×10
4cells/well. Various cultures were
incubated for different periods of time while being
exposed to one or more of the following: PAR1 agonists,
a-thrombin and TFLLR-NH2,a n dP A R 1a n t a g o n i s t ,
SCH79797 and resultant growth rates were quantified.
The level of pro-thrombin was 1-2 μM, and a concen-
tration of active thrombin in the 10 nM range was
almost certainly physiologically relevant [26]. The TRAP
analogue, TFLLR-NH2, can selectively activate PAR1 at
concentrations lower than 50 μM [27]. Thus, we
selected an a-thrombin concentration of 15 nM and a
TFLLR-NH2 concentration of 30 μMt od e t e r m i n ei f
these enzymes would stimulate proliferation of MKN45/
PAR1 and MKN28 cells. Cell numbers were counted
with a hemocytometer at 24, 48, 72 and 96 hrs after
seeding of cells.
Cell invasion assay
In addition to establishing that the activation of PAR1 in
a gastric carcinoma cell background can stimulate cell
replication, we wished to evaluate the ability of PAR1 to
stimulate cell invasion. Invasion of cells through matri-
gel was determined using a Transwell system (CHEMI-
CON) as described previously [28]. a-thrombin was
a d d e da t1 5n M ,T F L L R - N H 2 w a sa d d e da t3 0μMa n d
SCH79797 was added at 35, 70, or 150 nM to the cells
(0.5×10
6cells/well) in the upper well containing serum-
free medium. After the addition of fresh medium con-
taining 10% FBS to the lower chamber, incubation was
continued for 24 hr at 37°C. The cells on the underside
of the membrane were stained and dissolved in 10%
acetic acid for measurement of A560 nm. The A560 nm of
the MKN45/mock, MKN28 and MKN45/PAR1 cells
cultured under noted conditions were determined and
compared using the A560 nm of MKN45/mock and
M K N 2 8c u l t u r e du n d e raP A R 1a g o n i s t - f r e ec o n d i t i o n
as a baseline.
Measurement of NF-B Activation by Electrophoretic
Mobility Shift Assay
MKN45/mock and MKN45/PAR1 were treated for 0.5,
1, 2, 6, 12, and 24 hr with 15 nM a-thrombin. Nuclear
fractions were extracted from the cultured cells using
NE-PER (PIERCE, Rockford, IL, USA). Assays were per-
formed using an oligonucleotide with the NF-Bm o t i f ,
5′-AGTTGAGGGGACTTTCCCAGGC-3′,w h i c hw a s
labeled with biotin for chemiluminescence detection.
Nuclear extracts of MKN45/PAR1 and MKN45/mock
were isolated and a Gel mobility shift assay was per-
formed by incubating each of the nuclear extracts with
the labeled probe and competing oligonucleotides in
binding buffer. The complex was resolved by electro-
phoresis on a 5-20% SuperSep gel (Wako) in 0.5× TBE
buffer at 4°C, transferred to N
+nylon membrane, and
detected by streptavidin-HRP using a Lightshift chemilu-
minescence electrophoretic mobility shift assay (EMSA)
kit (PIERCE). Super-shift reactions were run as
described above with the exception that 2 μg of polyclo-
nal anti-NF-B-p50 and -p52 antibodies were used.
Assays of Tenascin-C levels in conditioned medium by
means of ELISA
The levels of high molecular-weight TN-C protein were
determined using an ELISA kit (IBL) for the conditioned
medium of MKN45/mock and MKN45/PAR1 at 3, 6,
and 12 hr after the addition of 15 nM a-thrombin. The
collected samples were concentrated by using VIVAspin
(Vivascience, Stonehouse, UK) ultra-filtration units and
incubated in 96-well ELISA plates for 1 hr at 37°C.
After washing out unreacted antibody, HRP-conjugated
anti-TN-C was added, followed by incubation for
30 min at 4°C, and the color intensity was determined
at 450 nm. Results were calculated from the mean
absorbance of duplicate wells.
Assays of TN-C initiated phosphorylation of EGFR
MKN45/PAR1 was separately exposed to 15 nM
a-thrombin for either 3 hr or 12 hr period. We then
collected each separate conditioned medium and filtered
it removing proteins with molecular weights lower than
200 kDa, including a-thrombin, and retained the high
molecular weight protein concentrate. The concentrate
then underwent two rounds consisting of a ten-fold
dilution with PBS followed by filtration to isolate the
same high molecular weights proteins. The level of a-
thrombin in the resultant concentrates was estimated by
means of SDS-PAGE and Western blot and was found
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initial cell cultures from which the concentrates were
derived. Subsequent separate cultures of MKN45/PAR1
cells underwent a 6 hr exposure to one of either of the
high molecular weight concentrates. The cultures
exposed to the concentrates derived from initial cultures
exposed to 15 nM a-thrombin for 12 hr were incubated
for 6 hr either in the presence or absence of TN-C-neu-
tralizing antibody (Clone BC24, 25 μg/ml). After incuba-
tion each culture exposed to concentrates was lysed,
and the lysate subjected to SDS-PAGE, Western blotting
and probing to quantify levels of phosphorylated EGFR.
Results
PAR1 mRNA is expressed in Gastric Cancer Cell Lines
The expression of PAR1 mRNA in seven gastric cancer
cell lines was evaluated by RT-PCR and was found to be
present in MKN28, MKN74, and NUGC3 cell lines (Fig-
ure 1A). Although, although a faint band was detected
for KATOIII cells, no RT-PCR signal for PAR1 was
detected for the NUGC2, MKN45, and TMK-1 cell lines
(Figure 1A).
Expression of PAR1 in MKN45 cells
Since MKN45 cells did not express PAR1, we selected
this gastric carcinoma-derived cell line as a ‘host’ cell
for PAR1 expression, in order to evaluate the functional
properties of PAR1 in a gastric carcinoma cell back-
ground. As shown in Figure 1B, transfection of MKN45
cells with pcDNA3.1-PAR1 bearing the human full
PAR1 coding sequence and a neomycin-resistance gene
yielded a receptor-expressing MKN45 cell line, selected
in the presence of G418.
PAR1-expressing MKN45 cells proliferate in response to a
PAR1-activating peptide and a-thrombin
a-thrombin clearly stimulated replication of MKN45/
P A R 1o v e ra4d a yt i m ef r a m e ,w i t hag r e a t e rt h a n2 -
fold increase in cell number relative to non-thrombin-
treated MKN45/PAR1 at 96 hr (Figure 3). The prolifera-
tion of MKN45/mock was not stimulated either by a-
thrombin or TFLLR-NH2 (Figure 2). Even in the
absence of a-thrombin, MKN45/PAR1 outgrew the
MKN45/mock at 96 hr, suggesting the presence of
receptor-activating proteinases in the growth medium.
Similarly, TFLLR-NH2 triggered an approximately 3-fold
increase in cell number, in treated compared with
untreated MKN45/PAR1 (Figure 4). Of particular signif-
icance, the PAR1-selective antagonist, SCH79797, in a
concentration-dependent manner, was able to block the
proliferative actions of both a-thrombin and TFLLR-
NH2 (Figures 3 and 4). The data thus indicated a PAR1-
Figure 1 The expression of PAR1 mRNA and protein in gastric cancer cell lines. (A) The expression of PAR1 mRNA in 7 gastric cancer cell
lines by RT-PCR. PAR1 mRNA was confirmed in MKN28, MKN74 and NUGC3. (B) Parent MKN45 cells and MKN45 cells transfected with pcDNA3.1-
empty-vector alone (designated as MKN45/mock) have no detectable expression of PAR1 protein, and MKN28 and MKN45 cells transfected with
PAR1 cDNA bearing pCDNA3.1 vector, which was treated 750 μg/ml G418 to select permanent PAR1 expressing clone, (designated as MKN45/
PAR1) was confirmed to continuously express high level PAR1 protein by immunoblotting (upper panel). The bottom panel showed a protein
band of a house keeping gene, GAPDH as a control. (The final dilution of PAR1 antibody was 1:500, GAPDH was 1:2000.)
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and TFLLR-NH2, demonstrating the presence of a func-
tional receptor in these cells.
PAR1 activation induces cell invasion
MKN45/PAR1 stimulated either by a-thrombin or by
TFLLR-NH2 showed significant acceleration of invasion
(Figure 5), whereas invasion of MKN45/mock was not
stimulated by either agonist (Figure 5). In regards to the
proliferative response, the PAR1 antagonist SCH79797
inhibited invasion triggered by both PAR1 agonists (Fig-
ure 5). This result further supports that the a-throm-
bin-mediated responses in MKN45/PAR1 were due to
PAR1 activation.
Figure 3 Proliferation assay in MKN45/PAR1 with a-thrombin stimulation. MKN45/PAR1 (1.0×10
4 cells/well) 96 hr after adding 15 nM a-
thrombin had significantly increased the number. SCH79797, selective PAR1 antagonist, significantly reversed the growth rate of MKN45/PAR1 at
35 and 70 nM and completely abolished thrombin dependent growth progression at 150 nM in the presence of 15 nM a-thrombin.
Figure 2 P r o l i f e r a t i o na s s a yi nM K N 4 5 / M o c k . This figure showed that the MKN45/mock (1.0×10
4 cells/well) 96 hr after adding 15 nM a-
thrombin or 30 μM TFLLRN-NH2, specific PAR1 agonist peptide, had not significantly increased the number.
Fujimoto et al. BMC Cancer 2010, 10:443
http://www.biomedcentral.com/1471-2407/10/443
Page 5 of 14PAR1-transfected MKN45 cells mimic features of PAR1-
expressing gastric cancer MKN28 cells
To compare MKN45/PAR1 with gastric cancer cells that
express endogenous PAR1 mRNA and PAR1 protein,
we also performed cell proliferation and invasion assays
with MKN28 cells, which express PAR1 (Figure 1A
&1B). Upon exposure to a-thrombin, both MKN28 cells
and MKN45/PAR1 cells presented an increase in cell
proliferation and invasion, and SCH79797 blocked the
effects of a-thrombin (Figure 6 &7). Thus, PAR1 in
Figure 4 Proliferation assay in MKN45/PAR1 with TFLLR-NH2. In the same way, MKN45/PAR1 adding 30 μM TFLLR-NH2 had significantly
increased the number, too. And SCH79797 siginificantly reversed the growth rate of MKN45/PAR1 in the presence of 30 μM TFLLR-NH2. (Date
were expressed as mean values ± SD from triplicate experiments.)
Figure 5 Invasion assay in MKN45/PAR1. Treatment of MKN45/PAR1 with 15 nM a-thrombin or 30 μM TFLLR-NH2 resulted in significant
enhancement (5 or 6 fold increment relative to untreated control) of its invasion potential. But treatment of MKN45/mock with same conditions
of a-thrombin or TFLLR-NH2 resulted in no significant enhancement. The inhibitory effect of the SCH79797 was clearly observed at 35 and 70
nM. There was the maximum inhibitory effect on the invasion ability of MKN45/PAR1 at 150 nM SCH79797. Basal invading activity was expressed
as an absorbance of 560 nm for MKN45/mock cells which were unexposed to a-thrombin. (Date were expressed as mean values ± SD from
triplicate experiments.)
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a-thrombin, resulting in cell proliferation and invasion.
PAR1 activation induces NF-B activation
Having established the ability of PAR1 activation to sti-
mulate both proliferation and invasion of MKN45/
PAR1, we next evaluated the ability of PAR1 activation
to stimulate transcriptional events. The EMSA showed
that the PAR1 agonist a-thrombin can induce the acti-
vation of NF-B within 30 min of treatment of the
MKN45/PAR1. The EMSA signal persisted for 24 hr
(Figure 8). MKN45/mock and MKN45/PAR1 not
exposed to a-thrombin did not present any retarded
EMSA bands (Figure 8). We performed a super-shift
Figure 6 Proliferation assay in MKN28. The effect of a-thrombin stimulation on cellular features of MKN28 cells intrinsically expressing PAR1.
This figure shows increases in cell proliferation rate of MKN28 cells when stimulated with 15 nM a-thrombin and the preventative effect of a
PAR1-antagonist, SCH79797, on the MKN28 cell proliferation. The assay was carried out according to the same procedure as that described in
Figure 2 legend.
Figure 7 I n v a s i o na s s a yi nM K N 2 8 . This shows elevated invasion functions of MKN28 cells caused by thrombin stimulation and the
concentration-dependent prevention effect of a PAR1-antagonist, SCH79797. (Date were expressed as mean values ± SD from triplicate
experiments.)
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Page 7 of 14Figure 8 Activation of NF-B assessed by EMSA analysis in MKN45/mock and MKN45/PAR1 by a-thrombin stimulation. The gel mobility
shift assay was performed on the whole nuclear extract from MKN45/mock and MKN45/PAR1 (in a 12 cm diameter dish) that were incubated in
the presence of 15 nM a-thrombin for 0.5, 1, 2, 6, and 24 hr. MKN45/mock samples showed no retardation bands but only intense broad signal
due to biotinylated NF-B cis-element ds-oligo probe on the gel. An arrow on left side of the middle figure indicates the NF-B/DNA binding
complex. In the super-shift assay, antibodies (2 μg) raised against NF-Bp50 and NF-Bp52 were mixed with nuclear extract obtained from PAR1-
transfectanted cells treated with 15 nMa-thrombin for 0.5 hr. A super-shifted band was clearly detected with NF-Bp50 antibody as marked by
an arrowhead, but not detected with NF-Bp52 antibody.
Figure 9 The mRNA expression of NF-B target genes by quantitative RT-PCR. We selected 10 target genes of NF-B that are concerned
with cell growth and invasion. Most of the mRNA expression were increased after 15 nM a-thrombin stimulation. The mRNA expression levels
of TN-C, Bcl-2, cIAP1 and EGFR reached more than 100 times the relative levels of the control values. Especially, TN-C mRNA expression level was
increased. The kinetics of mRNA expression following a-thrombin stimulation in MKN45/PAR1 are different depending upon type of genes
tested. The bar height indicates the calculated fold activation values for each time after stimulation with 15 nM a-thrombin. It was based on the
condition of no a-thrombin stimulation. (Date were expressed as mean values ± SD from triplicate experiments.)
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antibody (but not for the p52-targeted reagent), there
was a decrease in intensity of the more rapidly migrating
EMSA signal, with a concomitant increase in intensity of
the ‘super-shifted’ band (Figure 8). The ability of
a-thrombin to trigger a PAR1-mediated activation of
NF-B was thereby verified.
Dynamism of mRNA expression of NF-B target genes
induced by a-thrombin in PAR1-expressing cells
We next evaluated the spectrum of NF-B target genes
that might be activated by a- t h r o m b i ni nM K N 4 5 /
PAR1. For this purpose, we selected 10 target genes of
NF-B. A-thrombin treatment (15 nM, 3 hr) caused an
increase in mRNA expression levels for all NF-B target
genes tested, especially for TN-C, Bcl-2, cIAP1, and
EGFR (Figure 9). The levels of TN-C, Bcl-2, cIAP1, and
EGFR mRNA expression reached more than 100 times
the corresponding levels of the control values in
MKN45/PAR1. The increases in mRNA for these four
NF-B-stimulated genes were mirrored by increases in
the levels of the four corresponding proteins, as detected
by western blot analysis (Figure 10). When PAR1 activa-
tion was inhibited by SCH79797 or when NF-B activa-
tion was inhibited by the CAPE (25 μg/ml), there was a
substantial inhibition of the a-thrombin-triggered
increase in the mRNA for these four NF-Bt a r g e t
genes in MKN45/PAR1 (Figure 11).
High molecular-weight factors resulting from PAR1
activation can activate EGFR in an autocrine manner
We took notice of TN-C, because its mRNA expression
presented the greatest magnitude of increase by PAR1
activation. ELISA results showed that the quantity of
TN-C in the culture medium increased gradually up to
3 hr after the addition of a-thrombin and that the maxi-
mum level was detected 12 hr after a-thrombin treat-
ment in MKN45/PAR1 (Figure 12). A detectable
Figure 10 Detection of the proteins, which were high expression mRNA under a-thrombin, by immunoblotting.M K N 4 5 / P A R 1w e r e
stimulated with 15 nM a-thrombin for 3, 6, and 12 hr and harvested for preparing whole cell lysates. The clear extracts containing 100 μg
protein was developed on SDS-PAGE. The expression of TN-C, Bcl-2, cIAP1, EGFR and GAPDH protein, which was a house keeping gene product
as a control, were detected by Western blotting using specific antibodies against respective proteins (The final dilutions of TN-C, Bcl-2, cIAP1 and
EGFR antibodies were 1:500, GAPDH was 1:2000). The MKN45/PAR1 were harvested at 3, 6 and 12 hr after 15 nM a-thrombin stimulation and
whole cells were lysed using LIPA buffer. Significant EGFR protein expression was detected in MKN45/mock and unstimulated MKN45/PAR1. The
expression above basal level was clearly observed for TN-C, Bcl-2, cIAP1 and EGFR proteins 6 hr after addition of 15 nM a-thrombin.
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the addition of a-thrombin, and increased tyrosine-
phosphorylation of the EGFR was clearly detected fol-
lowing 12 hr of stimulation by a-thrombin in MKN45/
PAR1 (Figure 13).
We hypothesized that the increased activation/phos-
phorylation of the EGFR might be due to the autocrine
action of the increased TN-C or of other high molecu-
lar-weight constituents produced by the cells. To test
this hypothesis, two separate cultures of MKN45/PAR1
cells were exposed to a-thrombin, one for a period of 3
hr and the other for a period of 12 hr, and high molecu-
lar weight proteins were isolated and concentrated from
each of the resultant conditioned mediums. Subsequent
cultures of MKN45/PAR1 were incubated for 6 hr with
one of each of the resultant concentrates and activation/
phosphorylation of the EGFR was quantified and com-
pared. The lysates from the MKN45/PAR1, which were
incubated with concentrate (deficient in proteins smaller
than 200 kDa) derived from the 12 hr a-thrombin sti-
mulated conditioned medium presented an increase in
phospho-EGFR, but the lysates from the MKN45/PAR1
which were cultured with the concentrate derived from
the 3 hr a-thrombin stimulated conditioned medium
presented no detectable bands (Figure 14 left). The level
of TN-C was minimal in the concentrate derived from
the 3 hr a-thrombin stimulated conditioned medium,
but abundant in the concentrate derived from the 12 hr
a-thrombin stimulated conditioned medium. These
results clearly indicate that a-thrombin-stimulated
MKN45/PAR1 produced high-molecular-weight consti-
tuents (possibly, TN-C), which can activate EGFR in an
autocrine manner.
We suspected that TN-C would be present along with
constituents with sizes greater than 200 kDa. To deter-
mine if TN-C might be responsible for the ability of the
concentrated medium to activate EGFR, we repeated the
experiment described above in the presence of a TN-C-
neutralizing antibody. The antibody markedly reduced
the ability of the high-molecular-weight cutoff medium
to stimulate the phosphorylation of the EGFR (Figure 14
right). And we showed by means of histograms that
phosphor-EGFR signal quantitatively diminished in the
presence of TN-C-neutralizing antibody (Figure 15).
Figure 11 Effect of NF-B inhibitor CAPE and a PAR1 antagonist SCH79797 on trans-criptional activation by thrombin stimulation of
NF-B target genes. NF-B inhibitor or PAR1 antagonist was added at 25 μg/ml or 70 nM, respectively, to the culture medium with 15 nM a-
thrombin. Six hour later, the treated cells were harvested for preparing total RNA, which was subjected to quantification for mRNA expression of
four NF-B target genes, such as, TN-C, Bcl-2, cIAP1 and EGFR by real time RT-qPCR. Each mRNA expression level after 6 hr thrombin stimulation
is 100%, the suppressive effect of inhibitor or antagonist was expressed as % inhibition. (Date were expressed as mean values ± SD from
triplicate experiments.)
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Page 10 of 14The data indicates that TN-C can contribute in an auto-
crine manner to stimulate phosphorylation of EGFR.
Discussion
The main finding of our study is that activation of PAR1
triggers activation of NF-B and EGFR for a long per-
iod, and TN-C, which is overexpressed by PAR1 activa-
tion, may be associated with EGFR activations. Our data
n o ws h o wn o to n l yt h a tt h eh i s t o l o g i c a lp r e s e n c eo f
PAR1 is correlated with the pathological findings asso-
ciated with invasion and metastasis in gastric cancer
[22], but also that this receptor and its activating protei-
nases, including thrombin and other serine proteinases
[8] can be seen as mechanistically important factors
driving the process of gastric cancer cell proliferation
and invasion.
Because our work used a PAR1 null cell as the host
f o rP A R 1e x p r e s s i o n ,o u rd a t ac l e a r l yd e m o n s t r a t et h e
oncogenic potential of PAR1 itself in a gastric cancer
cell background, apart from factors other than PAR1
that can confer the oncogenic phenotype. Both the
absence of a-thrombin effects in the PAR1 null cells
and the ability of the PAR1-selective antagonist,
SCH79797, to block the actions of a-thrombin in
MKN45/PAR1 indicate that the actions of a-thrombin
were due to PAR1 activation and not to other a-throm-
bin targets, like PAR4 or triggering by metalloprotei-
nases [12].
Figure 12 TN-C concentration determined by ELISA in the
conditioned medium of a-thrombin stimulated MKN45/PAR1.
Six cm diameter dishes with 50% confluency of MKN45/mock,
MKN45/PAR1 were used for preparing the conditioned medium. a-
thrombin was added at 15 nM to 6 dishes with MKN45/PAR1, and
the conditioned medium was collected at indicated time (3, 6, and
12 hr) and cleared supernatant by centrifugation was subjected to
ELISA assay which can detect only high molecular TN-C. The
concentration of high molecular TN-C in the conditioned medium
was expressed as μg/ml. (Date were expressed as mean values ± SD
from triplicate experiments.)
Figure 13 Increases in EGFR protein expression and phosphorylation of EGFR at Tyr1173 in MKN45/PAR1 stimulated with a-thrombin.
MKN45/PAR1 were stimulated with 15 nM a-thrombin for 1, 3, 6, and 12 hr and harvested for preparing whole cell lysates. The clear extracts
containing 100 μg protein was developed on SDS-PAGE. We detected by western blotting experiment using an antibody raised against total
EGFR (dilution of 1: 500) was increased 3 hr after addition of 15 nM a-thrombin to MKN45/PAR1. But we detected using an antibody raised
against phosphotyrosine (Tyr1173) that tyrosine phosphorylation of EGFR (dilution of 1:500) was slightly increased 1 hr after addition of 15 nM a-
thrombin, and following 3 hr, phospho-EGFR was dramatically increased.
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Page 11 of 14Our qPCR analysis of the spectrum of NF-Bt a r g e t
genes up-regulated by PAR1 activation revealed quite a
number of proteins, for example TN-C, Bcl-2 and
cIAP1, for which up-regulation has been previously
associated with a tumorigenic phenotype (Figure 9&10).
The prolonged time frame over which the mRNAs levels
are elevated after a-thrombin stimulation (up to 12 hr)
implies that signals in addition to the one triggered by
PAR1 may be involved. For instance, the direct activa-
tion of PAR1 by a-thrombin or PAR1-activating peptide
w o u l db ee x p e c t e dt ob ed o w n - r e g u l a t e do v e rar e l a -
tively short time frame, as can be observed for the sti-
mulation of intracellular calcium transients [29,30] or
for the activation of Mitogen-activated protein kinase
(MAPK) (often maximal at 5 minutes, declining to base-
line within 1 hr). Yet, in contrast with a PAR1-activating
peptide, a-thrombin as an agonist is known to cause a
prolonged activation of MAPK and enhanced mitogen-
esis [31]. It has been hypothesized that these long-term
actions of a-thrombin, in contrast with the effects of
PAR-activating peptides may be mediated by receptors
and mechanisms other than those encompassing PAR1
[32]. Thus, although we also have shown that NF-B
and EGFR activation initially were triggered by activa-
tion of PAR1 in the early phase (Figures 8 &13) [19,33]
the sustained responses very likely are mediated by
‘feed-forward’ mechanisms, possibly involving the pro-
duction of autocrine stimulatory factors like the one(s)
detected in the concentrated cell supernatants and/or
the sequential and synergistic cooperation of several
transcription factors in addition to NF-B. This
sequence of events set in motion by PAR1 activation
may reflect a generalized ‘oncogenic signal matrix’ that
may be initiated by a variety of mitogenic agents like
thrombin.
Apart from cell-derived proteinases as potential auto-
crine/paracrine factors, our work points to the possible
autocrine importance of secreted TN-C that was
observed to be a PAR1-induced gene and that could be
recovered in concentrate of conditioned medium of cul-
tures of a-thrombin-treated MKN45/PAR1 (RT-PCR
data; ELISA assay and identification by mass spectro-
scopy). PAR1 activation accounted for a-thrombin-
Figure 14 Detection of phosholyrated EGFR by TN-C. The conditioned medium of PAR1/MKN45 culture pre-stimulation by 15 nM a-
thrombin for 3 and 12 hr was collected and partially purified by repeated concentration using ultra-filtration spin columns able to cutoff
macromolecules below 200 kDa. MKN45/PAR1 were incubated either with the concentrated conditioned medium for 6 hr, which were pre-
stimulated for 3 hr or 12 hr by 15 nM a-thrombin. These whole lysates of MKN45/PAR1 treated with the conditioned medium pre-stimulated for
12 hr by 15 nM a-thrombin was detected remarkably enhanced tyrosine phospholyration of the EGFR, but these whole lysates of MKN45/PAR1
with the conditioned medium pre-stimulated for 3 hr by 15 nM a-thrombin was not detected the tyrosine phospholyration of the EGFR (left).
The whole lysates of MKN45/PAR1 treated with the concentrated conditioned medium with TN-C-neutralizing antibody (25 μg/ml), which was
pre-stimulated for 12 hr by 15 nM a-thrombin, show no-increased in phosphor-EGFR protein quantity (right).
Figure 15 Phospho-EGFR signal quantitatively diminished in
the presence of TN-C-neutralizing antibody by histograms. The
phospho-EGFR signal quantitatively diminished in the presence of
TN-C-neutralizing antibody by histograms. The bar height indicates
the calculated fold activation values. It was based on the condition
with the concentrated conditioned medium, which was obtained
after at 3 hr 15 nM a-thrombin stimulation with or without TN-C-
neutralizing antibody. Data are expressed as intensity units obtained
by densitometric analysis. (Date were expressed as mean values ±
SD from triplicate experiments.)
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Page 12 of 14induced tyrosine phospholyration of EGFR in renal car-
cinoma cells [20]. We also confirmed that the EGFR
itself was elevated in response to PAR1 activation in
gastric carcinoma cells (Figures 9, 10 &13). Since the
EGF-like sequence repeats derived from TN-C can act
as agonists for the EGFR in terms of MAPK activation
[34], it is tempting to speculate that secreted TN-C
might act as an autocrine activator of the EGFR to
enhance the mitogenic effect of PAR1 activation.
Further, the high-molecular-weight fractions recovered
from the conditioned medium of a-thrombin-stimulated
MKN45/PAR1 cultures were able to enhance the phos-
phorylation of the EGFR (Figure 14 &15), in keeping
with the hypothesis that the a-thrombin-stimulated cells
can produce autocrine factors that can activate the
EGFR. That TN-C itself represents that factor is an
open question, since even the TN-C derived EGF repeat
sequences do not significantly trigger EGFR autopho-
sphorylation, although they do trigger EGFR-mediated
activation of MAPK [34]. Further, it is not yet known if
the EGF-like repeats in TN-C can activate the EGFR
when present in the intact TN-C sequence. Notwith-
standing, the high-molecular-weight fraction from the
MKN45/PAR1 concentrates were able to induce EGFR
phosphorylation, and the TN-C-targeted-neutralizing
antibody significantly reduced that effect (Figure 14
&15). The data thus imply an autocrine role for TN-C
in cancer cells that clearly merits further work to eluci-
date the mechanism. TN-C, an adhesion modulatory
extracellular matrix molecule, is implicated in signal
transduction, proliferation and invasion in various can-
cers [35-38]. Our results showed that TN-C was
involved in the PAR1-mediated EGFR transactivation in
cancer cells for the first time.
Conclusion
Finally, we showed that the signaling pathways that
responded to PAR1 activation involving the activation of
NF-B and transactivation of EGFR, which might be sti-
mulated by TN-C, resulted in an increase in gastric can-
cer cell proliferation and invasion. These data indicate
that PAR1 is deeply associated with gastric cancer pro-
gression, and thus a very attractive novel therapeutic
target for blocking the progression of invasive and meta-
static gastric cancers.
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